Çocuklarda Atopik Dermatit

Yıl 2020, Cilt: 12 Sayı: 2, 66 - 78, 01.04.2020

Mustafa Arga Koray Harmancı

Öz

Atopik dermatit çocukluk çağının en sık görülen kronik deri hastalığıdır. Tanı klinik
öykü ve fizik muayene bulguları temel alınarak günümüzde geçerliliği kanıtlanmış
klinik tanı kriterlerine göre konulur. Özellikle erken başlangıçlı, tedaviye yeterli
yanıt alınamayan ve deri tutulumunun yaygın olduğu ağır olgularda olası besin alerjisi
birlikteliğinin belirlenmesi ve tedavi yönetiminin tamamen farklı olduğu immün
yetmezlik ve genetik-metabolik hastalıklardan ayrıcı tanısının yapılması son derece
önemlidir. Tedavinin temelini tetikleyicilerden kaçınma, deri bakımı ve anti-inflamatuar
tedavi oluşturur. Tedavi başarısında düzenli hasta/aile eğitimi ve iyi hekimhasta
ilişkisi esastır. Ağır kliniğe sahip sistemik tedavi gerektiren olgularda ciddi yan
etkilere sahip olmayan dupulimab gibi yeni immünomodülatör tedavi yaklaşımları
klinik kontrolün sağlanmasında, yaşam kalitelerinin artmasında ve komorbidite gelişiminin
önlemesinde umut ışığı olmuştur.

Anahtar Kelimeler

Atopik, dermatit, çocuk, tanı, tedavi, izlem

Kaynakça

• 1. Boguniewicz M, Leung DYM. Atopic Dermatitis. In: Adkinson NF, Bochner BS, Burks AW, Busse WW, Holgate ST, Lemanske
• RF, O’Hei RE (eds). Middleton’s Allergy Principles and Practice. 8th edition. Philadelphia: Saunders Elsevier, 2014: 540-64.
• 2. Novak N, Leung DYM. Role of Barrier Dysfunction and Immune Response in Atopic Dermatitis. In: Leung DYM, Szefler
• SJ, Bonilla FA, Akdis C, Sampson HA (eds). Pediatric Allergy Principles and Practice. 3th edition. Philadelphia: Saunders Elsevier, 2016: 438-47.
• 3. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of
• symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733-43.
• 4. Kurtuluş A, Arga M, Asilsoy S, Avcil S, et al. Diagnosis and Management of Atopic Dermatitis: National Guideline 2018. Asthma Allergy Immunol 2018;16 (Suppl 2):1-95
• 5. Arga M. Atopic Dermatitis and Genetics. Asthma Allergy Immunol 2018;16:1-13.
• 6. Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011;365:1315-27.
• 7. Liang Y, Chang C, Lu Q. The genetics and epigenetics of atopic dermatitis-Filagrin and other polymorphisms. Clin RevAllergy Immunol. 2016; 51(3): 315-328.
• 8. Prescott S, Saffery R. The role of epigenetic dysregulation in the epidemic of allergic disease. Clin Epigenetics 2011; 2: 223- 32.
• 9. Herberth G, Bauer M, Gasch M, Hinz D, Röder S, Olek S, et al. Lifestyle and Environmental Factors and Their Influence
• on Newborns Allergy Risk study group. Maternal and cord blood miR-223 expression associates with prenatal tobacco smoke
• exposure and low regulatory T-cell numbers. J Allergy Clin Immunol. 2014; 133(2): 543-50.
• 10. Schneider L, Tilles S, Lio P, Boguniewicz M, et al. Atopic dermatitis: a practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295-9.
• 11. Perkin MR, Strachan DP, Williams HC, Kennedy CT, Golding J, Team AS. Natural history of atopic dermatitis and its relationship
• to serum total immunoglobulin E in a populationbased birth cohort study. Pediatr Allergy Immunol. 2004; 15: 221-229.
• 12. Bieber T, D’Erme AM, Akdis C, Traidl-Hoffmann C, Lauener R, Schäppi G, et al. Clinical phenotypes and endophenotypes
• of atopic dermatitis: Where are we, and where should we go? J Allergy Clin Immunol 2017; 139: 58-64.
• 13. Rudzki E, Samochocki Z, Rebandel P, Saciuk E, Galecki W, Raczka A, et al. Frequency and significance of the major and
• minor features of Hanifin and Rajka among patients with atopic dermatitis. Dermatology. 1994; 189: 41-46.
• 14. Eichenfield LF, Hanifin JM, Luger TA, Stevens SR, Pride HB. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol. 2003; 49: 1088-1095.
• 15.Wollenberg A, Oranje A, Deleuran M, Simon D, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis
• and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30: 729- 747.
• 16. Yavuz ST, Sahiner UM, Buyuktiryaki B, Soyer OU, Tuncer A, Sekerel BE, Kalayci O, Sackesen C. Phenotypes of IgEmediated
• food allergy in Turkish children. Allergy Asthma Proc. 2011;32(6):47-55.
• 17. Heinemann C, Schliemann-Willers S, Kelterer D, et al. The atopy patch test reproducibility and comparison of different evaluation methods. Allergy 2002; 57(7): 641-5.
• 18. Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015; 91(3): 185- 90.
• 19. Mowad CM. Contact dermatitis: Practice gaps and challenges. Dermatol Clin. 2016; 34(3): 263-7.
• 20. Gül Ü. Psoriasis. Sağlığın Başkenti Dergisi. 2010(16): 18-21.
• 21. Johnston G, Sladden M. Scabies: diagnosis and treatment. BMJ. 2005; 331(7517): 619-22.
• 22. Staab D, von Rueden U, Kehrt R, Erhart M, Wenninger K, Kamtsiuris P, et al. Evaluation of a parental training program
• for the management of childhood atopic dermatitis. Pediatr Allergy Immunol 2002; 13: 84-90.
• 23. Grillo M, Gassner L, Marshman G, Dunn S, Hudson P. Pediatric atopic eczema: the impact of an educational intervention. Pediatric Dermatol 2006; 23: 428-436.
• 24. Galli E, Neri I, Ricci G, Baldo E, Barone M, Fortina AB, et al. Consensus conference on clinical
• management of pediatric atopic dermatitis. Ital J Pediatr. 2016; 42:26.
• 25. Caubet JC, Eigenmann PA. Allergic triggers in atopic dermatitis. Immunol Allergy Clin North Am. 2010; 30: 289- 307.
• 26. Oszukowska M, Michalak I, Gutfreund K, Bienias W, Matych M, Szewczyk A, et al. Role of primary and
• secondary prevention in atopic dermatitis. Postepy Dermatol Alergol 2015; 32: 409-20.
• 27. Thompson MM, Tofte SJ, Simpson EL, Hanifin JM. Patterns of care and referral in children with atopic dermatitis and concern for food allergy. Dermatol Ther. 2006; 19(2): 91-6.
• 28. Nankervis H, Pynn EV, Boyle RJ, Rushton L, Williams HC, Hewson DM, Platts-Mills T. House dust mite reduction and
• avoidance measures for treating eczema. Cochrane Database Syst Rev. 2015 19;1: CD008426.
• 29. Miller DW, Koch SB, Yentzer BA, Clark AR, O’Neill JR, Fountain J, et al. An over-the-counter moisturizer is as clinically
• effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate
• atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol 2011; 10: 531-7.
• 30. Sidbury R, Tom WL, Bergman JN, Cooper KD, Silverman RA, Berger TG, et al. Guidelines of care for the management of
• atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol. 2014; 71: 1218-33.
• 31. Kezic S, Novak N, Jakasa I, Jungersted JM, Simon M, Brandner JM, et al. Skin barrier in atopic dermatitis. Front Biosci 2014; 19: 542-556.
• 32. Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary
• prevention of atopic dermatitis. J Am Acad Dermatol 2010; 63: 587-93.
• 33.Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines
• for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018; 32(5): 657-682.
• 34. Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with
• methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized,
• double-blind, controlled study. Br J Dermatol 2008; 158: 801-807.
• 35. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of
• atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014 Jul;71(1):116-32.
• 36. Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimusin
• the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ. 2005; 330(7490): 516.
• 37. El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci 2009; 54: 76-87.
• 38. Thaci D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, et al. Proactive disease management with
• 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348-1356.
• 39. Paller AS, Tom WL, Lebwohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment,
• a novel, nonsteroidal phosphodiesterase 4(PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75: 494-503.
• 40. Zane LT, Chanda S, Jarnagin K, Nelson DB, Spelman L, Gold LS. Crisaborole and its potential role in treating atopic dermatitis:
• overview of early clinical studies. Immunotherapy 2016; 8: 853-66.
• 41. SM. Hoy. Crisaborole ointment 2%: A review in mild to moderate atopic dermatitis. Am J Clin Dermatol 2017; 18: 837- 43.
• 42. Dabade TS, Davis DM, Wetter DA, Hand JL, McEvoy MT, Pittelkow MR, et al. Wet dressing therapy in conjunction with topical
• corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol 2012; 67: 100-6.
• 43. Lee M, Van Bever H. The role of antiseptic agents in atopic dermatitis.Asia Pac Allergy. 2014; 4(4): 230-40.
• 44. Silverberg NB. Atopic dermatitis prevention and treatment. Cutis. 2017; 100(3): 173; 177-192.
• 45. Hata TR, Audish D, Kotol P, et al. A randomized controlled double blind investigation of the effects of vitamin D dietary
• supplementation in subjects with atopic dermatitis. J Eur Acad Dermatol Venereol 2014; 28: 781–789.
• 46. Camargo CA Jr, Ganmaa D, Sidbury R, et al. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. J Allergy Clin Immunol 2014; 134:831.
• 47. Zhao M, Shen C, Ma L. Treatment efficacy of probiotics on atopic dermatitis, zooming in on infants: a systematic review and meta-analysis.Int J Dermatol. 2018; 57(6): 635-641.
• 48. Huang R, Ning H, Shen M, Li J, Zhang J, Chen X. Probiotics for the Treatment of Atopic Dermatitis in Children: A Systematic
• Review and Meta-Analysis of Randomized Controlled Trials. Front Cell Infect Microbiol. 2017; 7: 392.
• 49. Mansfield JA, Bergin SW, Cooper JR, Olsen CH. Comparative probiotic strain efficacy in the prevention of eczema in infants
• and children: a systematic review and meta-analysis. Mil Med 2014; 179: 580–92.
• 50.Wang D, Beck LA. Immunologic targets in atopic dermatitis and emerging therapies: an update. Am J Clin Dermatol 2016; 17: 425-43.
• 51. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderatetosevere atopic dermatitis. N Engl J Med 2014; 371: 130-139.
• 52.Wang HH, Li YC, Huang YC. Efficacy of Omalizumab in patients with atopic dermatitis: a systematic review and metaanalysis. J Allergy Clin Immunol 2016; 138: 1719-22.
• 53. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003; 112: 118-127.
• 54. von Kobyletzki LB, Bornehag CG, Hasselgren M, Larsson M, Lindström CB, Svensson Å.Eczema in early childhood is
• strongly associated with the development of asthma and rhinitis in a prospective cohort.BMC Dermatol. 2012; 12: 11.
• 55. van der Hulst AE, Klip H, Brand PL.Risk of developing asthma in young children with atopic eczema: a systematic review.J Allergy Clin Immunol. 2007; 120: 565-9.
• 56. Tsakok T, Marrs T, Mohsin M, Baron S, du Toit G, Till S, Flohr C.Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016; 137: 1071-1078.
• 57. Carlsten C, Dimich-Ward H, Ferguson A, Watson W, Rousseau R, Dybuncio A, et al. Atopic dermatitis in a high-risk cohort:
• natural history, associated allergic outcomes, and risk factors.Ann Allergy Asthma Immunol. 2013; 110: 24-8.
• 58. Bantz SK, Zhu Z, Zheng T. The Atopic March: Progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol 2014; 5(2): pii: 202.
• 59. Paller A, Jaworski JC, Simpson EL, Boguniewicz M, Russell JJ, Block JK, et al. Major Comorbidities of Atopic Dermatitis:
• Beyond Allergic Disorders. Am J Clin Dermatol. 2018 Dec;19(6):821-838.
• 60. Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019 Aug;123(2):144-151.
• 61. Oliveira C, Torres T. More than skin deep: the systemic nature of atopic dermatitis. Eur J Dermatol. 2019 Jun 1;29(3):250-258.
• 62. Misery L, Finlay AY, Martin N, Boussetta S, Nguyen C, Myon E, et al. Atopic dermatitis: impact on the quality of life of patients and their partners. Dermatology. 2007; 215(2): 123- 129.
• 63. Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases:
• a cross-sectional multicenter study among dermatological outpatients in 13 European countries. J Invest Dermatol. 2015; 135(4): 984-991.